Merck & Co.'s Q2 2021 earnings call revealed a strong recovery in business performance, particularly highlighting significant growth in oncology with KEYTRUDA and in the vaccine segment with GARDASIL. Leadership emphasized strides in recovering from the pandemic and projected continued robust growth, aligning with improved patient access and operational efficiency. The management's ability to maintain ongoing R&D investments, coupled with successful integration of the Organon spin-off, portrays a stable outlook. The positive tone and guidance updates likely support a favorable short-term impact on Merck's stock. 

[1]